Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:

Bristol’s Pfizer, AstraZeneca Deals Could Add Up To $2 Billion To R&D Budget

  • News

Executive Summary

Bristol-Myers Squibb's partnerships with AstraZeneca and Pfizer to develop several late-stage compounds may provide the company with $2 billion to support its research and development initiatives, the firm said

You may also be interested in...



Type 2 Diabetes Developers Take Heart: New Safety Hurdle Is Surmountable

The April 1-2 meeting of the Endocrinologic & Metabolic Drugs Advisory Committee ended in equivocal results for the sponsors involved, but sends an unequivocal message of hope to diabetes drug development companies: the new cardiovascular safety bar adopted by FDA in December is surmountable

Type 2 Diabetes Developers Take Heart: New Safety Hurdle Is Surmountable

The April 1-2 meeting of the Endocrinologic & Metabolic Drugs Advisory Committee ended in equivocal results for the sponsors involved, but sends an unequivocal message of hope to diabetes drug development companies: the new cardiovascular safety bar adopted by FDA in December is surmountable

Pfizer Restructures For A More Flexible Future

In a move that could position Pfizer for more drastic measures down the road, the pharma giant has reorganized its development and commercial operations into several business units designed to foster autonomy and financial responsibility in the areas of specialty medicine, primary care and emerging markets
Table

View full table

Related Content

In Vivo Pink Sheet Pink Sheet Pink Sheet Pink Sheet Pink Sheet Pink Sheet
Tags:
UsernamePublicRestriction

Register

PS048298

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By